Abbott Laboratories Corporation

Abbvie Inc.

Abbvie Bahamas Limited

Huaqing Liu

Marlon D Cowart

Lawrence A Black

Robert J Altenbach

Irene I Drizin

Gregory A Gfesser

Brian D Wakefield

Chen Zhao

Youssef L Bennani

Michael E Kort

Ramin Faghih

Gin C Hsieh

Teodozyj Kolasa

Andrew O Stewart

John R Koenig

Meena V Patel

Yi-Yin Ku

Jeffrey J Rohde

Anwer Basha

Kirill A Lukin

Sou-Jen Chang

Diana L Nersesian

Michael P Curtis

Yu-Ming M Pu

Michael J Coghlan

Catherine M McCarty

Yu-Ming Pu

Anil Vasudevan

Kevin R Woller

Marc J Scanio

Neil Wishart

Padam N Sharma

Jorge D Brioni

Robert J Gregg

Marie P Honore

Timothy A Esbenshade

Kathryn J Hancock, Legal Representative

Arthur A Hancock

David J Babinski

Philip R Kym

Clara I Villamil

Arthur Gomtsyan

Michael R Schrimpf

Jerome F Daanen

Kristine E Frank

Michael M Friedman

Eric A Voight

Kennan C Marsh

Kathy A Sarris

Maria A Argiriadi

Kerren Kalai Swinger

Eric C Breinlinger

Paul J Brackemeyer

Kathleen Mortell

Henry Q Zhang

Wesley J Dwight

Anurupa Shrestha

Bruce Clapham

J Martin Herold

Robert Gentles

Stacy A Van Epps

Kathleen M Phelan

Ana Aguirre

Ellen Yulin Tsai Chien

Wei Qiu

Thomas C Custer

Jill M Wetter

Maria G Beconi

Jae Y Lee

David J Hardee

Thomas R Vargo

Matthew P Webster

Andrew J Little

Zhenping Tian

Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R, R2, R, R, R, X, X, X, X, X, nad n are as defined herein, pharmaeceutical compositions 2C X, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use. 

Inhibitors of tyrosine kinase 2 mediated signaling

Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R, Z, Z, and n are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by Tropomysin receptor kinases (Trk). Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

Furo-3-carboxamide derivatives and methods of use

Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions of compounds of formula (I), methods for using such compounds and compositions, and a process for preparing the compounds.

Mercaptoamidine derivatives and methods of use

Compounds of formula (I) wherein R, R, R, R, R, R, and Rare defined in the description, are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).

Cyclopropyl amine derivatives

Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X, L, R, R, R, A, m, n, p, q, s, and positions a and b are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

TRPV1 antagonists

Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).

Macrocyclic benzofused pyrimidine compounds, compositions comprising such compounds, methods for making the compounds, and methods of treating and preventing the progression of diseases, conditions and disorders using such compounds and compositions are described herein.

Macrocyclic benzofused pyrimidine derivatives

Benzothiazole and benzooxazole derivatives and methods of use

Heteroaryl-fused macrocyclic 2,4-diaminopyrimidine compounds of formula (I) wherein W, G, G, Aand Rare defined in the description, compositions comprising such compounds, methods for making the compounds, and methods of treating and preventing the progression of diseases, conditions, and disorders using such compounds and compositions are described herein.

Heteroaryl-fused macrocyclic pyrimidine derivatives

Macrocyclic pyrimidine compounds, compositions comprising such compounds, methods for making the compounds, and methods of treating and preventing the progression of diseases, conditions, and disorders using such compounds and compositions are described herein.

Macrocyclic pyrimidine derivatives

Macrocyclic Spiro pyrimidine compounds of formula (I): compositions comprising such compounds, methods for making the compounds, and methods of treating and preventing the progression of diseases, conditions, and disorders using such compounds and compositions are described herein.

Macrocyclic spiro pyrimidine derivatives

The present application describes substituted pyrimidine compounds of formula (I) wherein X, A, R, R, R, R, R, R, R, R, R, p, q, r, v, and w are defined in the specification, compositions comprising such compounds, methods for making the compounds, and methods of treating and preventing the progression of diseases, conditions and disorders using such compounds and compositions.

Substituted pyrimidine derivatives

Bicyclic-substituted amines as histamine-3 receptor ligands

Amino heterocyclic linked pyrimidine derivatives

Growing community of inventors

Buffalo Grove, IL, United States of America

Huaqing Liu